Terminology Service < Semantic Lookup Platform

All terms in NCIT

Label	Id	Description
Zolpidem Tartrate	NCIT_C29553	[The tartrate salt of an imidazopyridine with non-benzodiazepine benzodiazepine-receptor agonist and sedative-hypnotic activities. Zolpidem binds selectively to the alpha 1 subunit of the omega-1 (BZ1) receptor of the gamma-aminobutyric acid type A (GABA-A) receptor-chloride ionophore complex, thereby opening neuronal chloride channels, hyperpolarizing neuronal cell membranes, and inhibiting neuronal firing. In contrast, benzodiazepines non-selectively bind to and activate all omega receptor subtypes, exhibiting anticonvulsant and myorelaxant activities in addition to a sedative-hypnotic activity.]
gp-120 Antigen	NCIT_C29554	[A recombinant HIV gp120 envelope protein with potential use in HIV vaccine therapy. Gp-120 antigen is used to elicit a gp120-specific T-cell response. (NCI04)]
gp100 Protein (184V)	NCIT_C29555	[A recombinant peptide derived from the human melanoma antigen glycoprotein 100 (gp100) with potential use in cancer immunotherapy. gp100 protein(184V) has a valine substitution at position 184. Vaccination with this peptide may evoke a cytotoxic T lymphocyte (CTL) response against tumor cells expression the gp100 antigen.]
gp100 Peptide-sensitized Autologous T-cells (CD4+ and CD8+)	NCIT_C29556	[A population of CD4+ and CD8+ T-cells isolated from a cancer patient that have been sensitized in vitro to the melanoma-associated antigen gp100. Infusion of gp100 peptide-sensitized autologous T-cells into the cancer patient may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against gp100-positive tumor cells, thereby decreasing tumor growth. (NCI04)]
rCD4/IgG	NCIT_C29557
rF-MUC1(DF3)/TRICOM Vaccine	NCIT_C29558	[A fowlpox vaccine containing the tumor-associated antigen mucin-1 (MUC1), found in pancreatic tumor cells, and a TRIad of COstimulatory Molecules (B7-1, ICAM-1 and LFA-3; TRICOM), which is designed to enhance antigen presentation and activation of immune responses critical for tumor destruction. Vaccination with this agent may elicit a host immune response against MUC1-expressing tumor cells.]
rF-PSA/PSMA/TRICOM	NCIT_C29559	[A synthetic fowlpox viral vaccine containing the tumor-associated antigens prostate specific antigen (PSA), prostate specific membrane antigen (PSMA), and a TRIad of COstimulatory Molecules (B7-1, ICAM-1 and LFA-3; TRICOM). Vaccination with this viral vaccine may enhance antigen presentation and activate cytotoxic T-cells against PSA- or PSMA-expressing tumor cells.]
Grade 5 Radiation Recall Reaction (Dermatologic), CTCAE	NCIT_C146513	[Death]
Grade 5 Radiculitis, CTCAE	NCIT_C146514	[Death]
Grade 5 Rash Acneiform, CTCAE	NCIT_C146515	[Death]
Grade 5 Rectal Anastomotic Leak, CTCAE	NCIT_C146516	[Death]
Grade 5 Rectal Fistula, CTCAE	NCIT_C146517
Grade 5 Rectal Hemorrhage, CTCAE	NCIT_C146518
Grade 5 Rectal Mucositis, CTCAE	NCIT_C146519	[Death]
Grade 5 Pulmonary Fistula, CTCAE	NCIT_C146510	[Death]
Grade 5 Pulmonary Valve Disease, CTCAE	NCIT_C146511	[Death]
Grade 5 Pyramidal Tract Syndrome, CTCAE	NCIT_C146512	[Death]
Rilimogene Glafolivec	NCIT_C29560	[A cancer vaccine consisting of a recombinant fowlpox virus encoding fragment of human prostate-specific antigen (PSA), PSA:154-163 (155L), and a TRIad of COstimulatory Molecules (B7-1, ICAM-1 and LFA-3) (TRICOM). Administration of this agent may induce a cytotoxic T cell response against PSA-expressing tumor cells. Dendritic cells infected with TRICOM vectors greatly enhance naive T-cell activation and peptide-specific T-cell stimulation. Fowlpox virus is an attractive vector because its genome is easy to manipulate and it is replication incompetent in mammalian cells.]
rMVA-PSA/PSMA/TRICOM	NCIT_C29561	[A cancer vaccine consisting of recombinant modified vaccinia Ankara (rMVA) encoding the prostate specific antigen (PSA), the prostate-specific membrane antigen (PSMA) and a TRIad of COstimulatory Molecules (B7-1, ICAM-1 and LFA-3) (TRICOM). Vaccination with PSA/PSMA in combination with TRICOM may enhance antigen presentation, resulting in the augmentation of a cytotoxic T cell (CTL) immune response against tumor cells over-expressing PSA or PSMA.]
Recombinant Vaccinia-MUC1-B7.1	NCIT_C29562